Merck & Co Inc

MRK

Equity

ISIN null / Valor 10683053

New York Stock Exchange, Inc (2026-10-02)

USD 144.30+0.34%

Merck & Co Inc
UMushroom community rating:

4.00 7 votes No rating yet

NegativeNeutralPositive

About company

Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and animal health products. Headquartered in Rahway, New Jersey, it sells treatments across oncology, infectious disease, cardiometabolic and immunology areas, with high-profile products such as the immuno‑oncology therapy pembrolizumab (Keytruda) and the HPV vaccine Gardasil anchoring its portfolio; it also operates a significant animal health division. The company generates revenue through worldwide commercialization of patented drugs and vaccines, supports those sales with sustained R&D investment and collaborations to advance a pipeline of small molecules, biologics and vaccine candidates, and is publicly traded on the New York Stock Exchange under the ticker MRK.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

61.2%1Y

40.7%3Y

77.3%5Y

Performance

30.4%1Y

26.6%3Y

25.1%5Y

Volatility

356013 M

Market cap (USD)

9,661,871

Daily traded volume (Shares)

99.38 / 98.28

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.00

7 votes

Performance:

3.93

Innovation:

4.33

Society:

4.13

Nature:

4.07

Lewis Bastos

Spain, 09 Feb 2026

A good investment with solid earnings

Esteban Muñoz

Spain, 26 Nov 2025

Merck remains a well-managed, diversified pharma company with solid earnings, a marquee oncology franchise, and a reliable dividend. It can be a sensible long-term hold — as long as you’re comfortable with the risk.